BRIEF published on 09/18/2024 at 07:05, 1 year 8 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 9 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 9 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 9 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 9 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 9 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 9 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 11 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 11 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 06/04/2026 at 21:10, 1 hour 4 minutes ago Taranis Updates Shareholders on Disbursements of Taranis Securities to Matachewan and McChip Shareholders
Published on 06/04/2026 at 18:25, 3 hours 49 minutes ago Touchstone Exploration Inc. Proposed Fundraise of US$10 Million to US$15 Million
Published on 06/04/2026 at 14:45, 7 hours 29 minutes ago Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
Published on 06/04/2026 at 14:30, 7 hours 44 minutes ago Predictiv AI's Shift Technologies Secures Multi-Phase Commercial Contract to Digitize and Scale Middle-Mile and Last-Mile Logistics for Prompt Xpress
Published on 06/04/2026 at 14:00, 8 hours 14 minutes ago Horizon Aircraft Appoints Richard Alexander as Chief Engineer of Certified Programs
Published on 06/04/2026 at 20:00, 2 hours 14 minutes ago Notes Reduction - Results of Consent Solicitation
Published on 06/04/2026 at 19:27, 2 hours 47 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/04/2026 at 18:30, 3 hours 44 minutes ago FROM DUPLANTIS TO PALTRINIERI, FAIR PLAY MENARINI KICKS OFF ITS 30TH EDITION
Published on 06/04/2026 at 17:57, 4 hours 17 minutes ago EQS-Adhoc: Viscom SE raises its forecast for incoming orders in the 2026 financial year following a major contract
Published on 06/04/2026 at 17:50, 4 hours 24 minutes ago Monport Laser Showcases Engraving Opportunities in Germany Ahead of World Cup 2026
Published on 06/04/2026 at 20:00, 2 hours 14 minutes ago Schneider Electric announces the reference share price the initial conversion/exchange ratio of its €850 million new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 and the results of the repurchase of the OC
Published on 06/04/2026 at 18:23, 3 hours 51 minutes ago Shareholders’ Meeting and board of directors’ meeting held on June 4, 2026
Published on 06/04/2026 at 18:00, 4 hours 14 minutes ago Information concerning the total number of voting rights and shares in the share capital as of May 29, 2026
Published on 06/04/2026 at 17:45, 4 hours 29 minutes ago Declaration of voting rights at the end of May 2026
Published on 06/04/2026 at 17:45, 4 hours 29 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
